头孢哌酮钠舒巴坦钠联合甲泼尼龙琥珀酸钠治疗新生儿肺炎的效果分析  

Effect analysis of sulbactam sodium/cefoperazone sodium combined with methylprednisolone sodium succinate in the treatment of neonatal pneumonia

作　　者：丁会 DING Hui(Department of Pediatrics,Pizhou People's Hospital,Pizhou 221300,China)

机构地区：[1]邳州市人民医院儿科,221300

出　　处：《中国现代药物应用》2025年第3期84-87,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探究头孢哌酮钠舒巴坦钠、甲泼尼龙琥珀酸钠联合用于新生儿肺炎(NP)的治疗效果。方法选取40例新生儿肺炎患儿,采用随机数字表法分为对照组和观察组,每组20例。对照组行头孢哌酮钠舒巴坦钠治疗,观察组行头孢哌酮钠舒巴坦钠+甲泼尼龙琥珀酸钠治疗。对比两组炎性因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)、基质金属蛋白酶9(MMP-9)]水平,症状(气促、咳嗽、发绀、发热、肺啰音)消失时间,肺功能指标[潮气量(VT)、最大呼气流速占预计值百分比(PEF%)],血气分析指标[血氧饱和度(SpO_(2))、动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2))],临床疗效。结果两组患儿治疗前IL-6、CRP、MMP-9对比差异较小(P>0.05);两组患儿治疗后IL-6、CRP、MMP-9较治疗前降低,且观察组IL-6(6.17±1.05)pg/ml、CRP(3.06±0.56)mg/L、MMP-9(146.24±14.93)ng/ml较对照组的(7.54±1.20)pg/ml、(4.93±0.86)mg/L、(172.77±16.04)ng/ml更低(P<0.05)。观察组气促、咳嗽、发绀、发热、肺啰音消失时间分别为(3.61±0.70)、(4.12±0.82)、(3.03±0.58)、(2.34±0.41)、(3.94±0.67)d,比对照组的(5.24±0.93)、(5.19±0.97)、(4.19±0.66)、(3.78±0.54)、(5.31±0.80)d更短(P<0.05)。两组患儿治疗前VT、PEF%对比差异较小(P>0.05);两组患儿治疗后VT、PEF%均较治疗前升高,且观察组VT(7.54±1.38)ml/kg、PEF%(81.39±8.15)%显著高于对照组的(6.15±1.20)ml/kg、(75.79±7.83)%(P<0.05)。两组患儿治疗前SpO_(2)、PaCO_(2)、PaO_(2)对比差异较小(P>0.05);两组患儿治疗后SpO_(2)、PaCO_(2)、PaO_(2)均较治疗前改善,且观察组SpO_(2)(93.10±2.65)%、PaO_(2)(87.17±5.02)mm Hg(1 mm Hg=0.133 kPa)明显高于对照组的(88.31±3.44)%、(80.59±5.30)mm Hg,PaCO_(2)(40.39±3.40)mm Hg低于对照组的(47.04±3.62)mm Hg(P<0.05)。观察组总有效率(95.00%)比对照组(65.00%)更高(P<0.05)。结论在新生儿肺炎治疗中,运用头孢哌酮钠舒巴坦钠、甲泼尼龙琥珀酸钠联合治疗方�Objective To explore the effect of sulbactam sodium/cefoperazone sodium combined with methylprednisolone sodium succinate in the treatment of neonatal pneumonia(NP).Methods 40 cases of neonatal pneumonia were selected and divided into control group and observation group by random number table method,with 20 cases in each group.The control group was treated with sulbactam sodium/cefoperazone sodium,while the observation group was treated with sulbactam sodium/cefoperazone sodium+methylprednisolone sodium succinate.Both groups were compared in terms of inflammatory factors[interleukin-6(IL-6),C-reactive protein(CRP),matrix metalloproteinase-9(MMP-9)],disappearance time of symptoms(shortness of breath,cough,cyanosis,fever,pulmonary rale),and pulmonary function indicators[tidal volume(VT),peak expiratory flow as a percentage of the predicted value(PEF%)],blood gas analysis indicators[blood oxygen saturation(SpO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2)),arterial partial pressure of oxygen(PaO_(2))],and clinical efficacy.Results Before treatment,there was little difference in IL-6,CRP and MMP-9 between the two groups(P>0.05).After treatment,IL-6,CRP and MMP-9 in both groups decreased compared with before treatment;the observation group had IL-6 of(6.17±1.05)pg/ml,CRP of(3.06±0.56)mg/L and MMP-9 of(146.24±14.93)ng/ml,which were lower than(7.54±1.20)pg/ml,(4.93±0.86)mg/L and(172.77±16.04)ng/ml in the control group(P<0.05).In the observation group,the disappearance time of shortness of breath,cough,cyanosis,fever and pulmonary rale were(3.61±0.70),(4.12±0.82),(3.03±0.58),(2.34±0.41)and(3.94±0.67)d,which were shorter than(5.24±0.93),(5.19±0.97),(4.19±0.66),(3.78±0.54)and(5.31±0.80)in the control group(P<0.05).Before treatment,there was little difference in VT and PEF% between the two groups(P>0.05).After treatment,VT and PEF%in both groups were increased compared with before treatment;VT and PEF%were(7.54±1.38)ml/kg and(81.39±8.15)% in the observation group,which were significantly higher

关 键 词：头孢哌酮钠舒巴坦钠 甲泼尼龙琥珀酸钠 新生儿肺炎 肺功能 

分 类 号：R722.135[医药卫生—儿科]